Anna H. Chen, Ph.D.

Anna is a Partner on the Frazier Life Sciences team and focuses on identifying and evaluating investment opportunities and creating new ventures.

Anna joined Frazier Life Sciences in 2018, where she focuses on private investments and company creation. She co-led FLS’ investments in, and currently serves on the boards of Alentis, Eyconis, and BlueWater Biosciences.

Anna has been co-founder of and played key roles in FLS’ investments in Lengo Therapeutics (acquired by Blueprint Medicines), SanReno Therapeutics (acquired by Novartis), Inipharm, and Attovia Therapeutics. In addition, she was instrumental in FLS’ investments in Amunix Pharmaceuticals (acquired by Sanofi), Architect Therapeutics, and Diagonal Therapeutics, among others.

Prior to joining FLS, Anna was a management consultant in L.E.K. Consulting’s life sciences practice. While at L.E.K., Anna advised biotechnology and pharmaceutical companies on strategic planning, organizational development, R&D, and business development strategy. Previously, Anna was an entrepreneurial fellow at Flagship Pioneering and a business mentor for the National Science Foundation Innovation Corps program.

Anna received her Ph.D. in Systems Biology and A.B. in Biochemical Sciences from Harvard University, where she was a National Science Foundation Graduate Research Fellow.